

# Anti-CD30 Therapies - Pipeline Insight, 2022

<https://marketpublishers.com/r/A411F3CAFE46EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: A411F3CAFE46EN

## Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Anti-CD30 Therapies - Pipeline Insight, 2022" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anti-CD30 Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Anti-CD30 Therapies Understanding

#### Anti-CD30 Therapies: Overview

CD30 (also known as TNFRSF8) is a 120-kD transmembrane protein of the tumor necrosis factor family. The protein is comprised of an extracellular domain, a transmembrane region and a cytoplasmic domain. The majority of antibodies against human CD30 recognize epitopes within the extracellular domain. CD30 signaling regulates peripheral T-cell responses, controlling T-cell survival, and downregulating cytolytic capacity. CD30 is expressed on activated T cells, NK cells, and B cells. It is characteristically expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma and Hodgkin lymphoma, among others. Studies have also shown a role of CD30 as a T-cell costimulatory molecule involved in Th1, Th2, and Th17 immune responses. The restriction of CD30 expression on normal cells makes it an attractive

candidate for targeted therapy. In studies, anti-CD30 antibodies alone display therapeutic efficacy, the newer agents markedly enhance antibody effectiveness through their conjugation with various cytotoxic agents. Hence, CD30 can serve both as a diagnostic marker for lymphocyte malignancies and as a target for therapy.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Anti-CD30 Therapies R&D. The therapies under development are focused on novel approaches for Anti-CD30 Therapies.

## Anti-CD30 Therapies Emerging Drugs Chapters

This segment of the Anti-CD30 Therapies report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Anti-CD30 Therapies Emerging Drugs

### Brentuximab vedotin - Seagen/Takeda

Brentuximab Vedotin (ADCETRIS) is an antibody-drug conjugate (ADC) therapy developed by Seagen and its Takeda Oncology. The ABC contains an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics' proprietary technology. This linker system makes the molecule stable in the bloodstream but to release MMAE upon internalization into CD30-expressing cells. Under the terms of the collaboration agreement, Seattle Genetics has U.S. and Canadian commercialization rights and Takeda has rights to commercialize ADCETRIS in the rest of the world.

### AFM13: Affimed

AFM13 is a tetravalent bispecific chimeric (anti-human CD30 x anti-human CD16A) recombinant antibody construct which is being developed to treat CD30-positive

malignancies. The molecule is currently in Phase II clinical evaluation for the treatment of Relapsed/Refractory CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides.

Further product details are provided in the report.....

### Anti-CD30 Therapies: Therapeutic Assessment

This segment of the report provides insights about the different Anti-CD30 Therapies drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players working on Anti-CD30 Therapies

There are approx. 10+ key companies which are developing the Anti-CD30 Therapies. The companies which have their Anti-CD30 Therapies drug candidates in the most advanced stage, i.e. Phase III include, Seagen/Takeda.

#### Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Anti-CD30 Therapies pipeline report provides the therapeutic assessment of the

pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

### Anti-CD30 Therapies: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Anti-CD30 Therapies therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anti-CD30 Therapies drugs.

### Anti-CD30 Therapies Report Insights

- Anti-CD30 Therapies Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

### Anti-CD30 Therapies Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

## Key Questions

### Current Scenario and Emerging Therapies:

How many companies are developing Anti-CD30 Therapies drugs?

How many Anti-CD30 Therapies drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Anti-CD30 Therapies?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anti-CD30 Therapies therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Anti-CD30 Therapies and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Seagen

Takeda Oncology

Cellular Biomedicine Group

Wuhan Bio Raid Biotechnology

Affimed

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.

Tessa Therapeutics

## Key Products

Brentuximab vedotin

CART 30

Anti-CD30 chimeric antigen receptor T-cell therapy

AFM13

F0002-ADC

TT 11

SGN-CD30C

## Contents

Introduction

Executive Summary

Anti-CD30 Therapies: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Anti-CD30 Therapies – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Anti-CD30 Therapies companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Anti-CD30 Therapies Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Brentuximab vedotin: Seagen/Takeda Oncology

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

AFM13: Affimed

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis



## Anti-CD30 chimeric antigen receptor T-cell therapy: Wuhan Bio Raid Biotechnology

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Anti-CD30 Therapies Key Companies

Anti-CD30 Therapies Key Products

Anti-CD30 Therapies- Unmet Needs

Anti-CD30 Therapies- Market Drivers and Barriers

Anti-CD30 Therapies- Future Perspectives and Conclusion

Anti-CD30 Therapies Analyst Views

Anti-CD30 Therapies Key Companies

Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Anti-CD30 Therapies

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for Anti-CD30 Therapies

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: Anti-CD30 Therapies - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/A411F3CAFE46EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A411F3CAFE46EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970